2023

1. Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial

   The Lancet Respiratory Medicine, Vol. 11, Núm. 10, pp. 894-904